Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Apr

Today In Oncology

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Claim Denials for Medicare Cancer-Related NGS Testing Show Uncertainty of Coverage

Radiotherapy Dosing for Head and Neck Squamous Cell Carcinoma

Extended Follow-up of Belzutifan Treatment for von Hippel-Lindau Disease-Associated RCC

MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC

Role of Pathologists in Improving Access to Safer More Effective Allogeneic Cell Therapies